Jackson 2022.
Study characteristics | ||
Methods | Randomised, parallel‐group, placebo‐controlled study | |
Participants | 290 total participants (age 6‐17 years) Main inclusion criteria:
|
|
Interventions | Mepolizumab administered SC every 4 weeks, 40 mg for 6‐11 year‐olds and 100 mg for 12‐17 year‐olds for 52 weeks | |
Outcomes | Primary
Secondary
|
|
Notes | Conference abstract. NCT03292588 | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Allocation is random |
Allocation concealment (selection bias) | Unclear risk | Details not provided |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | ClinicalTrials.gov reports triple masking (participant, care provider, investigator) |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | ClinicalTrials.gov reports triple masking (participant, care provider, investigator) |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Details not provided |
Selective reporting (reporting bias) | Unclear risk | Challenging to assess reporting bias from a short abstract |